{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T17:02:24Z","timestamp":1771261344485,"version":"3.50.1"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,13]]},"abstract":"<jats:p>Sickle cell disease (SCD) remains a challenging hematologic disorder, characterized by chronic hemolysis, vaso-occlusive events, and multi-organ complications. Hypertension, a prevalent comorbidity in SCD, poses significant clinical implications, exacerbating the complexities of disease management and impacting patient outcomes. Understanding the intricate interplay between SCD and hypertension is pivotal. Mechanistic insights uncover a landscape characterized by chronic hemolysis, endothelial dysfunction, altered nitric oxide bioavailability, and increased oxidative stress, contributing to elevated blood pressure and heightened cardiovascular risks in individuals with SCD. The diagnostic challenges inherent in identifying and monitoring hypertension in SCD patients necessitate novel approaches. Current treatment paradigms encompass a spectrum of lifestyle modifications, pharmacological interventions, and multidisciplinary care models. However, the limitations and complexities inherent in managing hypertension in SCD call for innovative strategies. Tailored approaches, personalized treatments, and emerging therapeutic avenues geared explicitly toward SCD patients mark a shift toward more effective management. Advancements in technology, including wearable devices and remote monitoring systems, present opportunities to revolutionize blood pressure monitoring, enhancing patient engagement and compliance while providing more accurate and frequent measurements. Moreover, the review underscores the importance of integrated care models and multidisciplinary collaborations. Collaborative frameworks involving hematologists, cardiologists, nephrologists, and primary care physicians are integral in optimizing hypertension management and addressing the specific needs of individuals with SCD.<\/jats:p>","DOI":"10.1097\/md.0000000000047703","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:00:42Z","timestamp":1771005642000},"page":"e47703","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Strategies and innovations in hypertension management for sickle cell patients: A narrative review"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4538-0161","authenticated-orcid":false,"given":"Emmanuel Ifeanyi","family":"Obeagu","sequence":"first","affiliation":[{"name":"Division of Haematology, Department of Biomedical and Laboratory Science, Africa University, Mutare, Zimbabwe"},{"name":"Department of Molecular Medicine and Haematology, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20260216","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1080\/17474086.2017.1379895","article-title":"The emerging challenge of optimal blood pressure management and hypertensive syndromes in pregnant women with sickle cell disease: a review.","volume":"10","author":"Lari","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"R2-20260216","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3233\/CH-189002","article-title":"Sickle cell disease: Classification of clinical complications and approaches to preventive and therapeutic management.","volume":"68","author":"Ballas","year":"2018","journal-title":"Clin Hemorheol Microcirc"},{"key":"R3-20260216","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1182\/blood-2015-08-618561","article-title":"Pathophysiology and treatment of pulmonary hypertension in sickle cell disease.","volume":"127","author":"Gordeuk","year":"2016","journal-title":"Blood"},{"key":"R4-20260216","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1093\/eurheartj\/ehz217","article-title":"Cardiovascular manifestations of sickle cell disease.","volume":"41","author":"Hammoudi","year":"2020","journal-title":"Eur Heart J"},{"key":"R5-20260216","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1517\/14740338.2016.1161021","article-title":"Cardiovascular safety of antipsychotics: a clinical overview.","volume":"15","author":"Polcwiartek","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"R6-20260216","doi-asserted-by":"crossref","first-page":"e37941","DOI":"10.1097\/MD.0000000000037941","article-title":"Management of diabetes mellitus patients with sickle cell anemia: challenges and therapeutic approaches.","volume":"103","author":"Obeagu","year":"2024","journal-title":"Medicine (Baltim)"},{"key":"R7-20260216","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/2040620716653729","article-title":"The potential of gene therapy approaches for the treatment of hemoglobinopathies: achievements and challenges.","volume":"7","author":"Goodman","year":"2016","journal-title":"Therap Adv Hematol"},{"key":"R8-20260216","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/heartjnl-2019-314810","article-title":"Sickle cell disease: at the crossroads of pulmonary hypertension and diastolic heart failure.","volume":"106","author":"Wood","year":"2020","journal-title":"Heart"},{"key":"R9-20260216","first-page":"465","article-title":"Prediction of sudden cardiac arrest in the general population: review of traditional and emerging risk factors.","volume":"38","author":"Ha","year":"2022","journal-title":"Can J Cardiol"},{"key":"R10-20260216","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/S0140-6736(16)00647-4","article-title":"Cardiovascular complications and risk of death in sickle-cell disease.","volume":"387","author":"Gladwin","year":"2016","journal-title":"Lancet (London, England)"},{"key":"R11-20260216","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4103\/nmj.NMJ_131_16","article-title":"Antihypertensive medicines prescriptions before and after the Nigeria hypertension society guidelines and prescriber\u2019s awareness of the guideline.","volume":"58","author":"Olowofela","year":"2017","journal-title":"Niger Med J"},{"key":"R12-20260216","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/ijns5020020","article-title":"Sickle cell disease \u2013 genetics, pathophysiology, clinical presentation and treatment.","volume":"5","author":"Inusa","year":"2019","journal-title":"Int J Neonatal Screening"},{"key":"R13-20260216","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1164\/rccm.201401-0065ST","article-title":"An official American thoracic society clinical practice guideline: diagnosis, risk stratification, and management of pulmonary hypertension of sickle cell disease.","volume":"189","author":"Klings","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"R14-20260216","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/nrneph.2015.8","article-title":"Sickle cell disease: renal manifestations and mechanisms.","volume":"11","author":"Nath","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"R15-20260216","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/jca.21511","article-title":"Red blood cell exchange: 2015 American society for apheresis consensus conference on the management of patients with sickle cell disease.","volume":"32","author":"Sarode","year":"2017","journal-title":"J Clin Apher"},{"key":"R16-20260216","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12919-020-00204-1","article-title":"Annual Academy of Sickle Cell and Thalassaemia (ASCAT) conference: a summary of the proceedings.","volume":"14","author":"Strunk","year":"2020","journal-title":"BMC Proceedings"},{"key":"R17-20260216","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1053\/j.seminhematol.2023.08.002","article-title":"Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa.","volume":"60","author":"Ally","year":"2023","journal-title":"Semin Hematol"},{"key":"R18-20260216","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.2830150102","article-title":"Impaired pentose phosphate shunt function in sickle cell disease: a potential mechanism for increased Heinz body formation and membrane lipid peroxidation.","volume":"15","author":"Lachant","year":"1983","journal-title":"Am J Hematol"},{"key":"R19-20260216","doi-asserted-by":"crossref","first-page":"e2020064","DOI":"10.4084\/mjhid.2020.064","article-title":"The evolving pharmacotherapeutic landscape for the treatment of sickle cell disease.","volume":"12","author":"Ballas","year":"2020","journal-title":"Mediterranean J Hematol Infect Dis"},{"key":"R20-20260216","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/j.pec.2016.07.026","article-title":"Patient empowerment, patient participation and patient-centerednessin hospital care: a concept analysis based on a literature review.","volume":"99","author":"Castro","year":"2016","journal-title":"Patient Educ Couns"},{"key":"R21-20260216","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/bloodadvances.2020001851","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.","volume":"4","author":"Brandow","year":"2020","journal-title":"Blood Adv"},{"key":"R23-20260216","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/HYPERTENSIONAHA.120.15873","article-title":"Evidence and recommendations on the use of telemedicine for the management of arterial hypertension: an international expert position paper.","volume":"76","author":"Omboni","year":"2020","journal-title":"Hypertension"},{"key":"R24-20260216","doi-asserted-by":"crossref","first-page":"baaa010","DOI":"10.1093\/database\/baaa010","article-title":"Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine.","volume":"2020","author":"Ahmed","year":"2020","journal-title":"Database"},{"key":"R25-20260216","doi-asserted-by":"crossref","first-page":"e13608","DOI":"10.2196\/13608","article-title":"Mobile apps for medication management: review and analysis.","volume":"7","author":"Tabi","year":"2019","journal-title":"JMIR mHealth uHealth"},{"key":"R26-20260216","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1007\/s00277-025-06264-7","article-title":"Hyperhemolysis in a sickle cell disease patient in pregnancy.","volume":"104","author":"Warncke","year":"2025","journal-title":"Ann Hematol"},{"key":"R27-20260216","doi-asserted-by":"crossref","first-page":"e36147","DOI":"10.1097\/MD.0000000000036147","article-title":"Psychosocial challenges of persons with sickle cell anemia: a narrative review.","volume":"102","author":"Essien","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"R28-20260216","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s40266-023-01014-8","article-title":"Management of older adults with sickle cell disease: considerations for current and emerging therapies.","volume":"40","author":"Oyedeji","year":"2023","journal-title":"Drugs Aging"},{"key":"R29-20260216","doi-asserted-by":"crossref","first-page":"3885979","DOI":"10.1155\/2022\/3885979","article-title":"Sickle cell disease in children and adolescents: a review of the historical, clinical, and public health perspective of sub-Saharanafrica and beyond.","volume":"2022","author":"Egesa","year":"2022","journal-title":"Int J Pediatr"},{"key":"R30-20260216","doi-asserted-by":"crossref","first-page":"117510","DOI":"10.1016\/j.jns.2021.117510","article-title":"Stroke and stroke prevention in sickle cell anemia in developed and selected developing countries.","volume":"427","author":"Bhattacharya","year":"2021","journal-title":"J Neurol Sci"},{"key":"R31-20260216","doi-asserted-by":"crossref","first-page":"8610","DOI":"10.1097\/MS9.0000000000004195","article-title":"Health equity in sickle cell disease: overcoming barriers to care in marginalized communities.","volume":"87","author":"Obeagu","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"R32-20260216","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1161\/CIRCULATIONAHA.106.179904","article-title":"Essential features of a surveillance system to support the prevention and management of heart disease and stroke: a scientific statement from the American Heart Association Councils on epidemiology and prevention, stroke, and cardiovascular nursing and the interdisciplinary working groups on quality of care and outcomes research and atherosclerotic peripheral vascular disease.","volume":"115","author":"Goff","year":"2007","journal-title":"Circulation"},{"key":"R33-20260216","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","article-title":"Pathophysiology of sickle cell disease.","volume":"14","author":"Sundd","year":"2019","journal-title":"Annu Rev Pathol"},{"key":"R34-20260216","doi-asserted-by":"crossref","first-page":"e1560","DOI":"10.1097\/MD.0000000000001560","article-title":"Effects of ACEIs versus ARBs on proteinuria or albuminuria in primary hypertension: a meta-analysis of randomized trials.","volume":"94","author":"Xu","year":"2015","journal-title":"Medicine (Baltim)"},{"key":"R35-20260216","first-page":"212249","article-title":"Therapeutic approaches to slowing the progression of diabetic nephropathy \u2013 is less best?","volume":"2013","author":"Vivian","year":"2013","journal-title":"Drugs Context"},{"key":"R36-20260216","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5114\/aoms.2018.74026","article-title":"Renin\u2013angiotensin system inhibitor attenuates oxidative stress induced human coronary artery endothelial cell dysfunction via the PI3K\/AKT\/mTOR pathway.","volume":"15","author":"Shi","year":"2019","journal-title":"Arch Med Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:02:18Z","timestamp":1771257738000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000047703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047703","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"assertion":[{"value":"2024-04-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}